American Association for Cancer Research (AACR) presentations are happening this weekend and into early next week (see image below for a few of those in our catalyst database). On first glance, CRDF's Onvansertib data in colorectal cancer and AGEN's anti-CTLA-4 antibody AGEN1181 cancer basket trial data look pretty good. Onvansertib appears to increase PFS to 5.6 months from 2-3 months, although typically the FDA and market like to see at least 6 months PFS in our experience. With biomarker segmentation (KRAS) CRDF may get there since PFS has not been reached in this subpopulations. AGEN1181 showed additional responses and a conversion of a partial response to a complete response. Our volatility/Big-mover analysis found them both to be possible single-digit to low double-digit movers on strong readouts. Let's see what the market has in store for these stocks on Monday.
Click on the home page, and sign up for our 30-day free trial (no credit card and locks in at super low intro rate after that), and see which AACR readout in our database shows the highest impact possible stock move from our Big-Mover analysis.
Update from Monday, 4/12/21: We've added comments on the SPPI, HOOK, and RUBY AACR presentations as well, to our forum post behind the free signup wall. At a high level, SPPI and RUBY provided minor updates from updates they already provided last month. HOOK provided immunogenicity data and it will be interesting to see if the immunological response elicited by its biologic vaccine(s) results in clinical responses in the coming months. For more details, see our forum post on AACR clinical read-outs (requires free signup).
